文献速递心律失常血脂与心血管预防

常见、罕见与体细胞遗传变异对房颤发病的贡献

Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该队列研究利用英国生物银行全基因组测序数据,纳入416 085名参与者、30 797例房颤事件,分析多基因风险评分、罕见变异基因集与克隆性造血体细胞变异对5年房颤发病的独立与联合贡献,并构建整合基因组模型IGM-AF,发现三种变异均与房颤相关,联合临床模型可提升预测与风险分层。

要点

  • 多基因风险评分、罕见变异基因集和CHIP变异均独立增加5年房颤风险。
  • 同时携带三种遗传驱动因素者5年房颤累积发病率至少为仅有一种驱动者的2倍。
  • IGM-AF联合CHARGE-AF临床模型可提高房颤预测与风险分类能力。

核心结论

  • 常见、罕见和体细胞变异对房颤基因组风险具有互补价值,整合遗传信息可增强房颤筛查与预防干预。

研究设计与样本

  • 队列研究,使用英国生物银行2006至2010年招募的40至69岁参与者的全基因组测序数据,随访房颤事件至医院记录、死亡登记和自报。
  • 共纳入416 085人(平均年龄56.6岁,标准差8.0;女性224 642人,占54.0%),房颤病例30 797例。

主要发现

  • 多基因风险评分每升高1个标准差,房颤风险比HR为1.65(95%CI 1.63-1.67;P<1×10^-8)。
  • 罕见变异基因集与房颤风险相关,HR为1.63(95%CI 1.52-1.75;P=1.46×10^-42)。
  • CHIP相关体细胞变异与房颤风险相关,HR为1.26(95%CI 1.15-1.38;P=1.41×10^-6)。
  • 同时具有常见、罕见和体细胞三种遗传驱动因素者5年房颤累积发病率至少为仅有一种驱动因素者的2倍。
  • IGM-AF联合CHARGE-AF的C统计量为0.80(95%CI 0.80-0.80),高于单独使用IGM-AF或CHARGE-AF;加入CHARGE-AF后净重分类指数为0.08(95%CI 0.07-0.09)。

临床怎么用

  • 可将多基因风险评分、罕见变异基因集和CHIP纳入房颤风险评价,识别高风险个体。
  • 在临床风险模型CHARGE-AF基础上联合IGM-AF,有助于改善房颤风险预测与风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atrial fibrillation (AF) has a complex genetic architecture involving common, rare, and somatic variants. The association between these components requires further investigation. OBJECTIVE: To examine the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to AF incidence, and develop an integrated genomic model (IGM-AF) for improved risk prediction. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used whole-genome sequence data from participants of the UK Biobank, with follow-up for AF events through hospital records, death registries, and self-report. The UK Biobank recruited participants aged 40 to 69 years in the UK between 2006 and 2010. Study data were analyzed from August 2022 to November 2024. EXPOSURES: IGM-AF comprising an AF polygenic risk score (PRS), a composite rare variant gene set (AFgeneset), and somatic variants associated with clonal hematopoiesis of indeterminate potential (CHIP). Clinical AF risk was estimated using the Cohorts for Heart and Aging Research in Genomic Epidemiology AF (CHARGE-AF) score. MAIN OUTCOMES AND MEASURES: The primary outcome was hazard ratios (HRs) for 5-year incident AF attributable to PRS, AFgeneset, CHIP, and their interactions. The predictive performance of IGM-AF and its components was quantified using HRs, C statistics, and reclassification indices. RESULTS: A total of 416 085 individuals (mean [SD] age, 56.6 [8.0] years; 224 642 female [54.0%]) with 30 797 AF cases were included. The PRS (HR per 1 SD, 1.65; 95% CI, 1.63-1.67; P < 1 × 10-8), AFgeneset (HR, 1.63; 95% CI, 1.52-1.75; P = 1.46 × 10-42), and CHIP (HR, 1.26; 95% CI, 1.15-1.38; P = 1.41 × 10-6) were associated with incident AF. The 5-year cumulative incidence of AF was at least 2-fold among individuals having all 3 genetic drivers (common, rare, and somatic drivers) compared with those with only 1 driver. Integration of IGM-AF with a clinical risk model (CHARGE-AF) showed higher predictive performance (C statistic, 0.80; 95% CI, 0.80-0.80) compared with IGM-AF and CHARGE-AF alone. The classification of the at-risk population for AF was improved when IGM-AF was added to CHARGE-AF (net reclassification index, 0.08; 95% CI, 0.07-0.09). CONCLUSIONS AND RELEVANCE: Results of this cohort study demonstrated the complementary value of common, rare, and somatic variants in shaping genomic AF risk. Leveraging comprehensive genetic information may enhance screening and preventive interventions for AF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Zhang R, Kim MS, Yin W, et al. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. JAMA Cardiol. 2025. PMID: 41060636. doi:10.1001/jamacardio.2025.3664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。